The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISTH 2024 | Novel treatments being explored for patients with hemophilia: highlights from ISTH 2024
Omolade Awodu, MBChB, MD, FMCPath, University of Benin, Benin City, Nigeria, gives an overview of the most exciting novel hemophilia treatments that were presented at ISTH 2024. First, in the XTEND-ed Phase III trial (NCT04644575), efanesoctocog alfa, a factor VIII (FVIII) replacement therapy, was well tolerated and showed great bleed control in adults, adolescents, and children. Secondly, the UNEBI study (jRCTs051190119) showed that for patients with hemophilia A with inhibitors treated with emicizumab, the administration of recombinant activated clotting factor VII (rFVIIa) as a bypassing agent was safe and effective, and did not increase the rates of thrombosis. This interview took place at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Bangkok, Thailand, and virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
